Theravance Biopharma (TBPH) Interest Coverage Ratio (2014 - 2026)
Theravance Biopharma (TBPH) posted quarterly Interest Coverage Ratio of 148.17 for Q1 2026, down 560.07% year-over-year from 32.21 in Q1 2025, and down 530.92% quarter-over-quarter from 34.38 in Q4 2025.
Theravance Biopharma (TBPH) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Interest Coverage Ratio for 13 consecutive years, with 148.17 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 560.07% year-over-year to 148.17; the TTM figure through Mar 2026 stood at 21.08 (up 558.14% YoY), while the FY2025 annual figure was 0.01, up 92.34% from the prior year.
- Interest Coverage Ratio declined to 148.17 in Q1 2026 per TBPH's latest filing, from 34.38 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 34.38 in Q4 2025 and bottomed at 148.17 in Q1 2026.
- Historically, Interest Coverage Ratio has averaged 21.09 across 5 years, with a median of 15.79 in 2024.
- Annual changes were most pronounced in 2025 — Interest Coverage Ratio soared 3459.63% — and 2026, when it tumbled 560.07%.
- Theravance Biopharma's Interest Coverage Ratio stood at 5.92 in 2022, then surged by 87.2% to 0.76 in 2023, then tumbled by 35.13% to 1.02 in 2024, then jumped by 3459.63% to 34.38 in 2025, then sank by 530.92% to 148.17 in 2026.
- Business Quant data shows TBPH's Interest Coverage Ratio at 148.17 in Q1 2026, 34.38 in Q4 2025, and 11.27 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -104.77 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -104.77 |
| Mar 31, 2026 | -148.17 |
| Dec 31, 2025 | 34.38 |
| Sep 30, 2025 | -11.27 |
| Jun 30, 2025 | -4.11 |
| Mar 31, 2025 | -22.45 |
| Dec 31, 2024 | -1.02 |
| Sep 30, 2024 | -17.20 |
| Jun 30, 2024 | -24.39 |
| Mar 31, 2024 | -17.82 |
| Dec 31, 2023 | -0.76 |
| Sep 30, 2023 | -14.38 |
| Jun 30, 2023 | -28.39 |
| Mar 31, 2023 | -45.29 |
| Sep 30, 2022 | -5.92 |
| Jun 30, 2022 | -12.58 |
| Mar 31, 2022 | -18.02 |
| Dec 31, 2021 | 3.05 |
| Sep 30, 2021 | -25.10 |
| Jun 30, 2021 | -5.52 |